- Acquired Lavie Bio (majority activity) for $15.3M, Jul 2025
- Acquired MicroBoost AI for AG platform for $3.5M, Jul 2025
- Raised $28M Public Offering, Jan 2021
About
Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of Evogene's offering is ChemPass AI™, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters, increasing the probability of success while reducing development time and costs. Evogene operates through subsidiaries focused on human microbiome-based therapeutics (Biomica Ltd), medical cannabis (Canonic Ltd), agricultural biologicals (Lavie Bio Ltd), agriculture chemicals (AgPlenus Ltd), and castor oil production solutions (Casterra Ltd). Evogene has repositioned itself around ChemPass AI as its core engine, serving two main verticals: Pharma (discovery of novel small-molecule therapeutics) and Agriculture (crop protection innovation and related ag-tech applications).
Funding history · 26 rounds · $246.4M total
Acquisitions · 2
Offices
Q&A
- What is Evogene's core technology?
- Evogene's core technology is ChemPass AI™, a proprietary generative AI engine designed to discover and develop novel small molecules for the pharmaceutical and agricultural industries.
- What industries does Evogene target with its AI platform?
- Evogene targets two main verticals with its ChemPass AI™ platform: Pharma, for the discovery of novel small-molecule therapeutics, and Agriculture, for crop protection innovation and related ag-tech applications.
- What was Evogene's most recent funding event?
- Evogene's most recent funding event was a Public Offering in July 2026, which raised $3,288,113. A.G.P./Alliance Global Partners participated in this round.
- When was Evogene founded and where is it headquartered?
- Evogene was founded in January 2002 and is headquartered in Rehovot, Israel.
- What was the amount of the PIPE funding round Evogene received in August 2024?
- In August 2024, Evogene received $5,500,000 in a PIPE funding round, with participation from Israel Innovation Authority and A.G.P./.
- What was the amount of the C Round funding Evogene received in December 2022?
- In December 2022, Evogene received $20,000,000 in a C Round funding, with Shanghai Healthcare Capital (SHC) participating.
- What was the amount of the Public Offering in March 2024?
- In March 2024, Evogene conducted a Public Offering that raised $7,300,000.
Team · 19
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | evogene.com |
|---|---|
| linkedin.com/company/100603 | |
| Wikipedia | en.wikipedia.org/wiki/Evogene |
| Wikidata | wikidata.org/wiki/Q6981538 |
Identifiers & details
| Legal name | Evogene Ltd. |
|---|---|
| Founded | 2002-1 |
| Employees (exact) | 38 |
| Wikidata QID | Q6981538 |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| Lavie Bio (majority activity) | 2025-07 | $15.3M |
| MicroBoost AI for AG platform | 2025-07 | $3.5M |
Radar intelligence
Patents
| EPO | 245 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | evogene.com |
|---|
Wikidata
| QID | Q6981538 |
|---|
Certificate / subdomain footprint
| Subdomains | 38 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 512838723 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה ציבורית |
| Incorporated | 1999-10-10 |
| Purpose | לעסוק בסוגי עיסוק שפורטו בתקנון |
| Liability | לא מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2006 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | גד פינשטיין 13 רחובות |